Markkinen et al

- 1 The impact of complement factor H-related protein gene deletions on kidney
- 2 transplantation
- 3 Running title: CFHR deletions in kidney transplantation
- 4 Markkinen Salla^{1†}, Lokki A. Inkeri^{2,3†}, Helanterä Ilkka⁴, Ritari Jarmo¹, Partanen Jukka¹, Meri
- 5 Seppo^{2,5}, Hyvärinen Kati^{1*}
- 6 ¹Research and Development, Finnish Red Cross Blood Service, Helsinki Finland
- 7 ²Translational Immunology Research Program and Department of Bacteriology and Immunology,
- 8 Faculty of Medicine, University of Helsinki, Helsinki, Finland
- ³Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
- ⁴Transplantation and Liver Surgery, Helsinki University Hospital and University of Helsinki, Helsinki,
- 11 Finland
- 12 ⁵Diagnostic Center, Helsinki University Hospital, Helsinki, Finland

```
13
```

- 14 ⁺ These authors contributed equally to this work
- 15

- 17 Keywords: Complement factor H-related, CFHR, kidney transplantation, gene deletion,
- 18 allograft rejection
- 19 Number of words: 3884
- 20 ^{*}Corresponding author
- 21 Kati Hyvärinen, PhD, Associate professor
- 22 Finnish Red Cross, Blood Service
- 23 Research and Development
- 24 Biomedicum Helsinki 1, Haartmaninkatu 8
- 25 00290 Helsinki, FINLAND
- 26 Phone +358 40 920 3083
- 27 <u>kati.hyvarinen@helsinki.fi</u>
- 28

¹⁶

Markkinen et al

29 ABSTRACT

30	We recently reported that a homozygous deletion in the complement factor H-related
31	(CFHR) locus predisposed kidney transplant patients to rejection. As donors carried intact
32	genes, the susceptibility may have resulted from alloimmune reaction to FHR proteins.
33	However, we found no evidence for anti-FH response. It is therefore possible that CFHR
34	deletions as such affect the rejection risk. Here, we used MLPA and WGS to fine-map and
35	sequence the CFHR region in rs7542235-GG patients, a SNP tagging for Δ CFHR3 $@1$ deletion.
36	Our results confirmed that all patients with this SNP harboured deletions of various sizes
37	encompassing CFHR1. Furthermore, patients with homozygous $\Delta extsf{CFHR3} extsf{D1}$ were
38	homozygous for rs6677604-A, a SNP tagging for deletions of <i>CFHR3</i> 21 locus, confirming that
39	allele A tags for deletion of both CFHR3 and CFHR1. Proteomics analyses in a larger
40	population demonstrated that rs7542235-G and rs6677604-A associate with expression
41	levels of several proteins involved in regulating alloimmune response. We observed that
42	while increasing the rejection risk, the $\Delta {\it CFHR3}$ 21 did not associate to baseline disease or
43	specific clinical characteristics. To conclude, the various deletion types found in patients
44	shared the deletion of <i>CFHR1</i> gene confirming its association to variant rs7542235. Also,
45	both deletion-tagging alleles are associated with altered expression of FHR proteins.

Markkinen et al

46 INTRODUCTION

Prior matching of human leukocyte antigen (HLA), ABO blood group types, and a negative anti-HLA cross-matching are the golden rule in kidney transplantation. Regardless, some of the patients still experience complications after kidney transplantation. In search of novel histocompatibility factors, a study by Steers *et al.*(1) reported that a homozygous gene deletion of *LIMS1*, and our previous study (2) reported that homozygous deletion in the complement factor H-related (*CFHR*) locus consisting of *CFHR3* and *CFHR1* genes were associated with acute rejection of the graft.

There are a few mutually non-exclusive mechanistic explanations to these findings. The 54 55 rejection may be related to alloimmune response by the patient against the protein missing from the patient but expressed by the graft, hence, as such not necessarily linked to the 56 57 function of the protein. Alternatively, the rejection risk may be related to the function of the protein missing from the patient. The functional effect can be direct, i.e., a result of the 58 59 missing protein, or caused by expression of the missing protein by the transplanted kidney, or it can be related to complex downstream networks. A deletion of a gene and adjacent 60 61 DNA segments may furthermore lead to changes in the expression of some other genes that can be identified, for example, using quantitative trait loci (QTL) (3–5) approaches. 62

63 Steers and co-workers, who reported association between LIMS1 gene deletion and graft 64 rejection in kidney transplantation, could identify a specific anti-LIMS1 antibody pointing to 65 alloimmune response against the LIMS1 protein missing from the patient. In our recent 66 study (6), we could not replicate the *LIMS1* deletion association in the set of 1025 Finnish 67 kidney transplantation patients and donors, but instead reported an association between CFH/CFHR locus deletion and acute rejection. The CFH/CFHR locus contains genes encoding 68 69 for factor H (FH), a major regulator of the alternative pathway (AP) of complement activation, and a set of related genes, CFHR1-5 (6,7). FH inhibits AP activation both in body 70 71 fluids and on cell surfaces. It binds to C3b, which has become bound to self surfaces, where 72 it inhibits local complement activation. In contrast, on "foreign" targets, such as microbial or virus surfaces, binding of FH to surface deposited C3b is weak allowing AP activation and 73 amplification to occur (8–10). The functions of FHR-1–5 proteins are becoming better 74 75 understood. As suggested already a long time ago (11) the FHRs promote complement

Markkinen et al

4

76 activity by competing with the master inhibitor FH (7). Genetic variants of CFH and CFHR1-5 77 have been linked to the pathogenesis of some kidney diseases, such as C3 glomerulopathy (12), atypical hemolytic uremic syndrome (13,14), IgA nephropathy (15–17) and lupus 78 79 nephritis (18). 80 In the present study, we wanted to understand the effects of $\Delta CFHR3-1$ gene deletions in 81 detail. We fine-mapped the deletion boundaries using multiple ligation-dependent probe 82 amplification (MLPA) and whole genome sequencing (WGS). We found that deletions of various sizes shared a homozygous deletion of CFHR1 gene indicating that rs7542235 allele 83 84 G tags for a heterozygous deletion of that locus. In addition to rs7542235, previous studies 85 have shown that another variant, rs6677604, tags for a deletion at the same genomic region

86 (16–18). We observed that a rs6677604 allele A tags for a heterozygous deletion of CFHR3–1

87 locus. Proteome analysis of patient plasma samples revealed that, in fact, the deletion-

tagging alleles rs7542235-G and rs6677604-A correlated with plasma protein level changes

of at least 23 and seven proteins, respectively, sharing six proteins. These shortlists meritfurther studies.

91

92 MATERIALS AND METHODS

93 Study cohort

94 The present study included 15 patients from the study of Markkinen et al. (6), who had rs7542235 GG-genotype tagging for the homozygous deletion in the $\Delta CFHR3-1$ locus. The 95 patients received their first kidney transplantation during 2007-2017 at the Helsinki 96 97 University Hospital, Helsinki, Finland. The characteristics of the whole study population 98 including the 15 patients with homozygous rs7542235-G and 1010 patients with heterozygous (AG) or homozygous non-deletion genotype (AA) are presented in **Table 1**. In 99 100 total of 199 (20%) rejections were observed in our study cohort. The primary outcome for 101 these patients was biopsy-proven acute rejection, including both antibody-mediated and T-102 cell-mediated rejections (19). Borderline changes were also included as rejections. The 103 characteristics of the 15 patients (8 in the rejection-group and 7 in the non-rejection-group) 104 with $\Delta CFHR3-1$ -deletion tagging rs7542235 GG-genotype are presented in **Table 2**.

Markkinen et al

5

105	DNA samples were extracted from whole blood at the time of histocompatibility testing for
106	transplantation, and serum samples were collected for complement-dependent cytotoxic
107	crossmatch to detect alloantibodies before and after transplantation at the Finnish Red
108	Cross Blood Service, Helsinki, Finland. The clinical data were extracted from the Finnish
109	Transplant Registry, which is a national follow-up registry obliged by law (Table 1).
110	
111	Genotyping and imputation
112	Genotyping and imputation procedures are explained in more detail in Markkinen et al. (6).
113	Briefly, the genotyping was performed at the Finnish Institute of Molecular Medicine
114	(FIMM), Helsinki, Finland using Illumina's Infinium Global Screening array-24 v2.0 with multi-
115	disease drop-in. The genotyped data were imputed with Finnish SISu v3 reference panel
116	consisting of high-coverage WGS data from THL Biobank cohorts (N=1768) (Pärn et al.
117	manuscript in preparation). The variant rs7542235 tagging for CFHR-deletion was imputed
118	and had an estimated quality measurement value, INFO-score, of 0.98. The other variant
119	investigated, rs6677604 tagging for CFHR-deletion was also imputed and had an INFO-score

120 of 0.99.

121

122 Multiplex ligation-dependent probe amplification

123 MLPA was performed for 15 homozygous rs7542235-G patients (eight with rejection, seven

124 without rejection) to screen the copy number variations in *CFH/CFHR* genomic region.

Additionally, we performed the analysis for control patients including eight individuals with

126 heterozygous AG-genotype (four with rejection, four without rejection) and eight individuals

127 with homozygous AA-genotype (four with rejection, four without rejection). The detailed

description of MLPA procedure is provided in the **Supplementary data**.

129

130 Whole genome sequencing

131 WGS was previously performed for three rs7542235 GG patients with rejection. The results

and detailed information about the WGS for these samples are provided in the main text

Markkinen et al

6

139	statistics for the WGS run are presented in Supplementary Table S2 .
430	A state of the MICC. A state of the construction Table CO
138	base pairs. The coverage depth for the sequenced samples was 7–17x. More detailed
137	input reads for each sample were around 200–500 million, and the length of reads was 151
136	NovaSeq S4 NS4-300 run. The number of aligned bases for each sample was 20–50 Gb. The
135	performed at FIMM, Helsinki, Finland, and the samples were sequenced with Illumina's
134	patients with GG-genotype (five with rejection, two without rejection). Sequencing was
133	and supplementary data of our previous publication (6). Here, we sequenced seven more

140

141 Western blot for FH and FHR proteins

142 In total of 15 serum samples from nine rs7542235 GG patients (five with rejection, four

143 without rejection) were available for western blot analysis of FH and FHR-1 expression.

144 From the 15 serum samples, nine were collected before transplantation (pre-tx) and six

were collected after transplantation (post-tx). The detailed methods for western blot are
provided in the **Supplementary data**.

147

148 Expression quantitative trait loci (eQTL) analyses

149 In the eQTL analyses, we used three databases to see the impact of $\Delta CFHR3-1$ deletion

150 tagging variant rs7542235 to gene expression: 1) The FIVEx browser

151 (<u>https://fivex.sph.umich.edu/</u>) eQTL data from blood vessel and kidney samples from the

152 EBI eQTL catalogue (4); 2) the eQTLGen Consortium database (<u>https://www.eqtlgen.org/</u>)

including cis-eQTL, trans-eQTL and eQTS (associations between polygenic scores and gene

expression levels) data from 37 datasets (3) from blood samples; and 3) the Human Kidney

155 eQTL Atlas (<u>https://susztaklab.com/Kidney_eQTL/index.php</u>) including four studies with

- total of 686 microdissected human kidney tubule samples (5). Each of these three databases
- 157 share data from the Genotype-Tissue Expression Consortium (GTEx). We used the same
- databases to also see the impact of an additional $\Delta CFHR3-1$ deletion tagging variant
- rs6677604 on gene expression. All the results are included regardless of P-value.

Markkinen et al

161 Protein quantitative trait loci (pQTL), gene ontology and Reactome analyses

- 162 We used Olink (n = 1225) and SomaScan (n = 865) pQTL plasma proteomics data of healthy
- 163 blood donors from FinnGen project (<u>https://www.finngen.fi/en</u>) to see whether the
- 164 $\Delta CFHR3 \square 1$ deletion tagging variants rs7542235 and rs6677604 have effect on protein
- 165 expression. Results with P-value of $<3.49 \times 10^{-06}$ were included. These genes were also
- included in the gene ontology (GO) enrichment analysis (<u>https://geneontology.org/</u>) for
- 167 each three aspects of biological process, molecular function and cellular component, and
- 168 Reactome pathway database (<u>https://reactome.org/</u>).
- 169

170 Other statistical analyses

- 171 Characteristics of patients in **Table 1** and **Table 2** were described by medians and
- interquartile ranges (IQRs) or ranges, and frequencies and percentages. The comparison
- between the two groups of patients with rs7542235 GG-genotype and patients with AA/AG-
- 174 genotype (**Table 1**), and GG-genotype with rejection and GG-genotype without rejection
- (**Table 2**) were analyzed using the nonparametric Mann-Whitney U-test for non-normally
- distributed data (recipient age, follow-up time, PRA I and II, HLA eplet mismatch, HLA I eplet
- 177 mismatch and HLA II eplet mismatch), Pearson's chi-square test for recipient sex, Fisher's
- 178 exact test for primary diagnosis, or Student's t-test for normally distributed data (cold
- ischemia). The significance of variation of PRA-values in **Table 2** was not analyzed due to the
- 180 low frequency count. P-values <0.05 were considered statistically significant.
- 181

182 RESULTS

183 Characteristics of the study population

184 We previously reported genetic association between reduced rejection-free survival and

- 185 $\Delta CFHR3$ 21-deletion tagging variant rs7542235 genotype GG (6). 15 out of 1025 patients
- 186 were homozygous for this deletion-tagging variant, 4% belonging to rejection-group and 1%
- to non-rejection group. The characteristics of the study groups are shown in Table 1 and
- 188 **Table 2**. In total of 53% of rs7542235 GG patients had rejection, whereas the percentage

Markkinen et al

189 a	mong AG/AA	patients was on	y 19	(P-val	ue <0.001). No si	gnificant	difference	in
-------	------------	-----------------	------	--------	-----------	----------	-----------	------------	----

190 characteristics between those with rejection and without rejection among patients with

- 191 rs7522235 GG genotype were found (Table 2). There was no enrichment of diagnoses
- 192 known to be linked to *CFHR* locus.
- 193
- 194 Multiplex ligation-dependent probe amplification
- 195 MLPA confirmed that all 15 rs7542235 GG patients had homozygous deletions of different
- sizes at the *CFH/CFHR* locus, three different types are depicted in the **Figure 1**. The shared
- 197 feature of all samples was a homozygous deletion of *CFHR1* gene, indicating that variant
- 198 rs7542235 tags for deletion of that gene. Patients with deletion type 1 were also
- homozygous for A allele of the other variant rs6677604, while patients with deletion type 2
- and 3 were heterozygous AG for that variant indicating that it tags for a deletion of both
- 201 CFHR3 and CFHR1.
- As assumed, eight patients with rs7542235 genotype AA had no deletions at the CFHR locus,
- and eight patients with heterozygous AG genotype carried a heterozygous deletion
- encompassing both the CFHR1 and CFHR3 genes (Figure 2). The patients with rs7542235 AA
- 205 genotype were also homozygous GG for the variant rs6677604, while heterozygous
- rs7542235 AG patients were also heterozygous AG for variant rs6677604.
- 207

208 Whole genome sequencing

- 209 WGS (Figure 3) confirmed the results of MLPA; all ten rs7542235 GG patients had
- 210 homozygous deletions of different sizes but they shared the deletion of the CFHR1 gene. In
- addition to homozygous deletions, WGS results confirmed the findings of MLPA results
- showing that 5 out of 10 patients carried heterozygous deletions. The **Figure 4** represents
- the deletion type 3 in more detail.
- 214
- 215 Western blot of FH and FHR proteins

Markkinen et al

9

The western blot run showed that 9/9 of serum samples from individuals with rs7542235 GG genotype lacked the FHR-1 protein (Figure 5). The results are in line to those obtained from genetic MLPA and WGS analyses. The more detailed description and genotypes for

- 219 each serum sample is shown in **Table 3**.
- 220

221 Expression quantitative trait loci analyses

222 Both tagging variants are intronic, the rs7542235 residing in first intron of LOC100996886, a 223 complement factor H-related protein 3-like pseudogene and rs6677604 residing 3' downstream of 224 exon 11 of CFH. To understand whether the $\Delta CFHR321$ deletions or the intronic tagging 225 variants rs7542235 and rs6677604 regulate the expression of other genes, we screened the 226 eQTL databases for both variants. The results are presented in **Table 4**. According to FIVEx 227 database, the allele G of rs7542235 and allele A of rs6677604 were both associated with the lower expression levels of CFHR1, -3, and -4 genes. Additionally, the variant rs6677604 was 228 229 also associated with increased expression level of CFH and lower expression of KCNT2. All 230 the results from FIVEx were from GTEx study, including data from blood vessel and kidney 231 samples. Based on the eQTLGen Consortium database consisting of only blood samples, 232 both variants were associated merely with the higher expression level of CFH. When 233 screening the Human Kidney eQTL Atlas having samples from kidney tubule, we found two 234 statistically significant associations in CFHR1 and CFHR3 genes. The beta-values for these 235 findings were negative indicating reduced expression.

236

237 *Protein quantitative trait loci, gene ontology and Reactome* analyses

238 When analysing the effect of variant rs7542235 allele G on protein expression, total of 23 239 proteins were shown to be differentially expressed. The Olink results showed three genes to 240 be associated with P-value <2.97 x 10^{-8} ; *CFH, CFHR2* and *CFHR5* (**Table 5**), each gene having 241 a positive beta-value and thus meaning an increase in expression. SomaScan data resulted 242 in total of 22 proteins to be differentially expressed with P-value <3.5 x 10^{-6} . In concordance 243 to Olink results, also SomaScan showed an increase in expression for *CFH* and *CFHR5*, and as 244 was assumed, the Δ *CFHR1* deletion tagging variant resulted in decreased expression of

Markkinen et al

10

245 CFHR1 gene. Other differentially expressed genes for rs7542235 included, e.g., prolactin 246 receptor (PRLR) with decreasing expression levels and Kirre Like Nephrin Family Adhesion Molecule 1 (KIRREL1) with increased expression. For variant rs6677604, the allele A was 247 associated with two differentially expressed genes with P-value <2.87 x 10⁻⁴; CFH and 248 Leukocyte Immunoglobulin Like Receptor A5 (LILRA5). For both genes, the beta-value was 249 positive indicating increasing expression levels. Olink result for this variant resulted in five 250 differentially expressed genes with P-value <1.78 x 10⁻⁹. Like variant rs7542235, also 251 rs6677604 was associated with decreased level of CFHR1. 252 In the GO enrichment analysis of molecular function annotation, four out of 23 genes (CFH, 253 254 CFHR1, CFHR2 and CFHR5) for variant rs7542235 were associated with three functions of complement component C3b binding, opsonin binding and complement binding with false 255 discovery rates (FDR) of 8.06 x 10⁻⁶, 3.71 x 10⁻⁵ and 5.34 x 10⁻⁵, respectively (**Supplementary** 256 table S4). For the other variant rs6677604, GO enrichment analysis annotation showed an 257 association of two out of seven genes (CFH and CFHR1) for complement component C3b 258 binding pathway with FDR 2.76 x 10⁻². The Reactome analysis showed that four out of 23 259 260 genes (CFH, CFHR1, CFHR2 and CFHR5) were associated to two pathways; regulation of complement cascade and complement cascade with FDR 1.00 x 10⁻³ for both. For variant 261 rs6677604, there were three associations; CFH and CFHR1 were associated to regulation of 262 complement cascade and complement cascade with FDR 9.04 x 10^{-4} for both, and *NAGLU* 263 was associated to Sanfilippo syndrome with FDR 0.004. (Supplementary table S4). 264

Markkinen et al

266 DISCUSSION

267 We reported earlier that homozygosity for variant rs7542235 allele G, tagging deletions at 268 the *CFHR3–1* locus, predisposed patients to kidney allograft rejection. To understand better 269 the mechanisms behind the association, we here fine-mapped the deletion boundaries and 270 studied the effects of the gene deletion on protein levels. In addition to our previously 271 reported variant, we also investigated another variant, rs6677604, known to tag for deletion 272 at the CFHR3-1 locus. Our results show that kidney transplantation patients with GG 273 genotype of deletion-tagging variant rs7542235 have gene deletions of various sizes and 274 types in the CFHR locus. The different deletion types, however, shared the complete 275 deletion of the CFHR1 gene pointing to its primary role. Also, we found that patients with 276 homozygous $\Delta CFHR3 \square 1$ deletion are homozygous for rs6677604-A genotype. Patients with 277 other types of deletion combinations (Deletion type 2 and 3, Figure 1) were heterozygous 278 AG for rs6677604 indicating that allele A tags for a deletion of both CFHR1 and CFHR3. With 279 the support of our results and previous findings (20,21), it is plausible to assume that 280 patients with deletion type 2 carry two heterozygous deletions of $\Delta CFHR321$ and $\Delta CFHR124$. 281 Patients with deletion type 3, in addition to carrying a heterozygous deletion $\Delta CFHR3$ -282 CFHR1, consistently with previous studies, are likely to carry a heterozygous CFHR3::CFHR4 283 hybrid gene (22,23). The lack of expressed FHR-1 protein in homozygous rs7542235-G 284 individuals was confirmed by Western blot analysis. We also showed by using both eQTL 285 databases and proteomics studies that the rs7542235 allele G and rs6677604 allele A are 286 associated with differences in plasma expression levels of various proteins, not merely with those encoded by genes at the CFH/CFHR locus but others as well. 287

288 The spectrum of kidney diseases in patients with homozygous *CFHR1* deletion was typical to 289 adults receiving a kidney transplant in Finland. It did not involve complement-mediated 290 diseases. Two patients carrying the deletion type 3 were diagnosed with IgA nephropathy 291 and one with glomerular disorder in granulomatosis with polyangiitis. Previously, the 292 CFHR3::CFHR4 hybrid gene has been observed in C3G (22) and atypical haemolytic uremic 293 syndrome (23). This suggests that the polymorphism may in different patients result in 294 varying manifestations of kidney disease. Similarly, other patients with the homozygous 295 *CFHR1* deletion did not share any particular type of kidney disease.

Markkinen et al

12

296 Sequence and copy number variations in the CFH and CFHR1-5 gene cluster have been 297 linked to the kidney disorders such as C3 glomerulopathy (12), and IgA nephropathy (15). It 298 has been shown that homozygous deletion $\Delta CFHR3-1$ and deficiency of FHR-1 and -3 have a 299 protective effect in IgA nephropathy (24) and age-related macular degeneration (AMD) (25). A hybrid form of the CFHR3-1 gene has been associated with an increased risk for C3 300 301 glomerulopathy (12). This finding indicates that an overactivity of FHRs is linked to complement-mediated diseases. The increased activity of FHRs is assumed to be due to a 302 303 tendency to make dimers that more efficiently compete with FH. Only an autoimmune form 304 of haemolytic uremic syndrome, with autoantibodies against FH, is linked to CFHR3-1 305 deficiency.

306 The capillaries of kidney glomerulus are continually perfused by large volumes of blood, so 307 the FH and FHR complement proteins present in plasma are in direct contact with the 308 membrane. Due to filtration of water into urine, the concentration of complement proteins 309 increases as plasma flows through the kidney, thus exposing these glomerular cells and 310 surfaces to higher concentrations of FH/FHR proteins than are found elsewhere in the body. 311 Furthermore, the protection against spontaneous complement attack on the glomerulus 312 relies exclusively on the effect of the soluble protector FH, whereas cellular surfaces of the 313 body are further protected by surface bound complement regulators including membrane 314 cofactor protein (MCP, CD46), decay accelerating factor (DAF, CD55) and protectin (CD59). 315 These factors could explain why kidney is relatively sensitive to complement dysregulation 316 (26).

317 A recent study by Sun et al. discovered that a mismatch in LIMS1 was associated with death-318 censored graft loss and are expression quantitative trait loci in immune cells for GCC2, a 319 gene encoding for a protein involved in mannose-6-phosphase receptor recycling and thus 320 possibly triggering immune responses in the recipient (27). As shown by the eQTL and pQTL 321 results, it is plausible that the homozygous deletion of *CFHR1* shared by all patients 322 influences the expression levels of other CFHR genes and proteins, and thus could alter the complement activation. Among the FHR proteins, FHR-1 is most abundant in plasma with a 323 324 typical molar ratio of the FHR-1 dimer to FH being approximately 0.3:1. The variant rs7542235 allele G is associated with an increased expression of FH and decreased 325

Markkinen et al

13

326 expression of FHR-1. While FH inhibits complement activation and protects human 327 endothelial cells, FHR-1 has an opposite effect. FH is a regulator of the C3 convertase and 328 promotes degradation of C3b and opsonization of foreign pathogens with iC3b that results 329 in phagocytosis. FHR-1 competes with FH for these activities, thereby increasing 330 complement activation. It thus indirectly promotes C3/C5 convertase activity and 331 complement membrane attack complex assembly. By inhibiting FH binding to C3b, FHR-1 332 promotes C5a formation and consequent inflammation. In the absence of FHR-1 and FHR-3, 333 local FH binding and activity would be increased, resulting in suppression of complement 334 activation, but, on the other hand, possibly also to an impaired ability to handle injured 335 tissue components. Additionally, the disruption of the balance of FH/FHR protein concentrations and FHR-1 and -5 dimerization patterns due to genetic deletions and 336 337 emergence of hybrid genes likely lowers the threshold of adverse immunological events in 338 the presence of an additional triggering event such as organ transplant. 339 Besides CFH/CFHRs, differentially expressed genes based on proteomics data included PRLR 340 and KIRREL1 for variant rs7542235 and PRLR and LILRA5 for rs6677604. The downregulated 341 prolactin (PRL) is an endocrine hormone that has several physiological effects including 342 immune system regulation and anti-inflammatory effects. It can trigger the production of 343 proinflammatory cytokines, also having several anti-inflammatory effects that can reduce 344 hyperinflammation (28). Prolactin exerts its effects through PRL receptors (PRLRs). The 345 upregulated KIRREL1, also known as NEPH1, is a member of the NEPH protein family and is 346 expressed in kidney podocytes, cells involved in ensuring size- and charge-selective 347 ultrafiltration. Mutations in *KIRREL1* gene have been linked to hereditary nephrotic 348 syndrome (29). Leukocyte immunoglobulin-like receptors (LILRs) are a family of inhibitory or 349 stimulatory receptors expressed by immune cells, and several members of the LILR family 350 recognize major histocompatibility complex class I (30). The function of the upregulated 351 LILRA5 is currently unknown, but it has been shown to induce secretion of several 352 proinflammatory cytokines, which suggests the roles of this protein in triggering innate immune response (31,32). The increased levels of LILRA5 have also been linked to antibody-353 354 mediated rejection after kidney transplantation (30) Overall, the eQTL analysis indicates a 355 potentially enhanced inflammatory response in the presence of the tagging variants.

Markkinen et al

14

356	In conclusion, we found that rs7542235 allele G tags a deletion of the <i>CFHR1</i> gene. We also
357	found that rs6677604 allele A tags for a deletion of the whole <i>CFHR3</i> 21 locus. The plasma
358	proteomics studies also show that both variants are associated with an altered expression of
359	FH/FHR proteins thus revealing a novel level of intricate regulation of complement system
360	by the genetic polymorphisms of the CFH region.
361	
362	AUTHOR CONTRIBUTIONS STATEMENT
363	S. Markkinen, J. Partanen and K. Hyvärinen planned the study, interpreted the results and
364	drafted the manuscript; S. Markkinen, I. Lokki and K. Hyvärinen carried out the genome data
365	analyses; the MLPA and western blot analyses and interpretation of the results of these

methods were carried out by I. Lokki, S. Markkinen and S. Meri; S. Markkinen executed *in*

367 silico database searches; J. Ritari combined the pQTL summary statistics; I. Helanterä

provided clinical data and expertise; all authors contributed to the final version of themanuscript.

370

371 CONFLICT OF INTEREST STATEMENT

372 The authors have no conflicts of interest to declare.

373

374 ACKNOWLEDGEMENT

375 We want to thank Maria Semenova, BSc, for help in collecting the serum samples. We also 376 want to thank Lauri Snellman, biotechnology engineer, for help in laboratory with MLPA, 377 and Marcel Messing, PhD, for help with the western blot method. The THL Biobank's SISu v3 Imputation reference panel used for the research were obtained from THL Biobank (study 378 379 number: BB2019 12). We thank all study participants for their generous participation in 380 biobank research. We also want to thank the Sequencing Informatics Team, FIMM Human 381 Genomics, University of Helsinki for the WGS analyses. We want to acknowledge the 382 participants and investigators of FinnGen study. The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following 383

Markkinen et al

- industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb
- 385 (and Celgene Corporation & Celgene International II Sàrl), Genentech Inc., Merck Sharp &
- 386 Dohme LCC, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US
- 387 Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, Novartis Pharma AG, and
- 388 Boehringer Ingelheim International GmbH. Following biobanks are acknowledged for
- 389 delivering biobank samples to FinnGen: Auria Biobank (www.auria.fi/biopankki), THL
- 390 Biobank (<u>www.thl.fi/biobank</u>), Helsinki Biobank (<u>www.helsinginbiopankki.fi</u>), Biobank
- 391 Borealis of Northern Finland (<u>https://www.ppshp.fi/Tutkimus-ja-</u>
- 392 <u>opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx</u>), Finnish Clinical Biobank
- 393 Tampere (<u>www.tays.fi/en-</u>
- 394 <u>US/Research and development/Finnish Clinical Biobank Tampere</u>), Biobank of Eastern
- 395 Finland (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-
- 396 <u>FI/Potilaalle/Biopankki</u>), Finnish Red Cross Blood Service Biobank
- 397 (<u>www.veripalvelu.fi/verenluovutus/biopankkitoiminta)</u>, Terveystalo Biobank
- 398 (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/) and Arctic Biobank
- 399 (https://www.oulu.fi/en/university/faculties-and-units/faculty-medicine/northern-finland-
- 400 <u>birth-cohorts-and-arctic-biobank</u>). All Finnish Biobanks are members of BBMRI.fi
- 401 infrastructure (<u>www.bbmri.fi</u>). Finnish Biobank Cooperative -FINBB (<u>https://finbb.fi/</u>) is the
- 402 coordinator of BBMRI-ERIC operations in Finland. The Finnish biobank data can be accessed
- 403 through the Fingenious[®] services (<u>https://site.fingenious.fi/en/</u>) managed by FINBB.

404

405 FUNDING STATEMENT

- 406 The study was supported by funding from the Government of Finland VTR funding,
- 407 Munuaissäätiö (to S. Markkinen) and Suomen Transplantaatiokirurginen yhdistys ry (to S.
- 408 Markkinen), the State Subsidy to Hospitals (TYH2019311 and TYH2022315 to S. Meri),
- 409 Helsinki University Hospital Diagnostic Center funds (Y780023006, to S. Meri) and Sigrid
- 410 Jusélius Foundation (to S. Meri). FinnGen is funded by two grants from Business Finland
- 411 (HUS 4685/31/2016 and UH 4386/31/2016) and twelve industry partners (AbbVie Inc,
- 412 AstraZeneca UK Ltd, Biogen MA Inc, Celgene Corporation, Celgene International II Sarl,
- 413 Genentech Inc, GlaxoSmithKline, Janssen Biotech Inc. Maze Therapeutics Inc., Merck Sharp

Markkinen et al

- 414 & Dohme Corp, Novartis, Pfizer Inc., Sanofi). The funders and biobanks had no role in study
- 415 design, data collection and analysis, decision to publish, or preparation of the manuscript.

416

417 ETHICS STATEMENT

- The study conforms to the principles of the Declaration of Helsinki and has been approved
- 419 by the ethics committee of Helsinki University Hospital (HUS/1873/2018) and the Finnish
- 420 National Supervisory Authority for Welfare and Health (V/9161/2019).

Markkinen et al

17

421 REFERENCES

4122 423	Steers NJ, Li Y, Drace Z, D'Addario JA, Fischman C, Liu L, et al. Genomic Mismatch at <i>LIMS1</i> Locus and Kidney Allograft Rejection. New England Journal of Medicine. 2019;380(20):1918–28.
424	
4225 426 427	Markkinen S, Helanterä I, Lauronen J, Lempinen M, Partanen J, Hyvärinen K. Mismatches in gene deletions and kidney-related proteins as candidates for histocompatibility factors in kidney transplantation. Kidney Int Rep. 2022;7(11):2484–94.
428	
429 430 431	Võsa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, et al. Large-scale cis- and trans- eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet. 2021 Sep 1;53(9):1300–10.
432	
483 434	Kwong A, Boughton AP, Wang M, Vandehaar P, Boehnke M, Abecasis G, et al. FIVEx: an interactive eQTL browser across public datasets. Bioinformatics. 2022 Jan 15;38(2):559–61.
435	
4536 437 438	Liu H, Doke T, Guo D, Sheng X, Ma Z, Park J, et al. Epigenomic and transcriptomic analyses define core cell types, genes and targetable mechanisms for kidney disease. Nat Genet. 2022 Jul 1;54(7):950–62.
439	
4540 441 442	Markkinen S, Helanterä I, Lauronen J, Lempinen M, Partanen J, Hyvärinen K. Mismatches in gene deletions and kidney-related proteins as candidates for histocompatibility factors in kidney transplantation. Kidney Int Rep. 2022;7(11):2484–94.
443	
4 7 44 445 446	Lucientes-Continente L, Márquez-Tirado B, Goicoechea de Jorge E. The Factor H protein family: The switchers of the complement alternative pathway. Vol. 313, Immunological Reviews. Immunol Rev; 2023. p. 25–45.
447	
4848 449 450	Rodríguez De Córdoba S, Esparza-Gordillo J, Goicoechea De Jorge E, Lopez-Trascasa M, Sánchez- Corral P. The human complement factor H: Functional roles, genetic variations and disease associations. Mol Immunol. 2004 Jun;41(4):355–67.
451	
4952 453 454	Meri S, Pangburn MK. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci U S A. 1990;87(10):3982–6.

Markkinen et al

491

18

41506 457	Meri S. Self-nonself discrimination by the complement system. FEBS Lett. 2016 Aug 1;590(15):2418– 34.
458	
41519 460	Närkiö-Mäkelä M, Hellwage J, Tahkokallio O, Meri S. Complement-regulator factor H and related proteins in otitis media with effusion. Clin Immunol. 2001;100(1):118–26.
461	
4 <u>1622</u> 463	Malik TH, Lavin PJ, De Jorge EG, Vernon KA, Rose KL, Patel MP, et al. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J Am Soc Nephrol. 2012 Jul;23(7):1155–60.
464	
4 1635 466	Józsi M, Licht C, Strobel S, Zipfel SLH, Richter H, Heinen S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood. 2008;111(3):1512–4.
467	
41648 469 470	Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 2010;115(2):379–87.
471	
41752. 473	Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 2011 Feb;43(4):321–9.
474	
41785 476 477	Yeo SC, Liu X, Liew A. Complement factor H gene polymorphism rs6677604 and the risk, severity and progression of IgA nephropathy: A systematic review and meta-analysis. Nephrology (Carlton). 2018 Dec 1;23(12):1096–106.
478	
41779 480 481	Xie J, Kiryluk K, Li Y, Mladkova N, Zhu L, Hou P, et al. Fine mapping implicates a deletion of CFHR1 and CFHR3 in protection from IgA nephropathy in Han Chinese. Journal of the American Society of Nephrology. 2016;27(10):3187–94.
482	
41883 484	Tao J, Tan M, Li LL, Chu H, Song D, Tan Y, et al. Genetic Variant CFH rs6677604 Might Play a Protective Role in lupus Nephritis. Am J Med Sci. 2021 Mar 1;361(3):336–43.
485	
41896 487 488	Roufosse C, Simmonds N, Clahsen-Van Groningen M, Haas M, Henriksen KJ, Horsfield C, et al. A 2018 Reference Guide to the Banff Classification of Renal Allograft Pathology. Transplantation. 2018;102(11):1795–814.
489	
42900	Abarrategui-Garrido C, Martínez-Barricarte R, López-Trascasa M, Rodríguez De Córdoba S, Sánchez-

Corral P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel

Markkinen et al

492 493 494	genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood [Internet]. 2009 Nov 5 [cited 2024 Jun 19];114(19):4261–71. Available from: https://pubmed.ncbi.nlm.nih.gov/19745068/
495	
42916 497 498	Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 2010;115(2):379–87.
499	
5020 501 502 503	Piras R, Breno M, Valoti E, Alberti M, latropoulos P, Mele C, et al. CFH and CFHR Copy Number Variations in C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Front Genet [Internet]. 2021 Jun 11 [cited 2024 Jun 19];12. Available from: https://pubmed.ncbi.nlm.nih.gov/34211499/
504	
52035 506 507 508	Piras R, Valoti E, Alberti M, Bresin E, Mele C, Breno M, et al. CFH and CFHR structural variants in atypical Hemolytic Uremic Syndrome: Prevalence, genomic characterization and impact on outcome. Front Immunol [Internet]. 2023 Jan 30 [cited 2024 Jun 19];13. Available from: https://pubmed.ncbi.nlm.nih.gov/36793547/
509	
52140 511	Kiryluk K, Novak J. The genetics and immunobiology of IgA nephropathy. J Clin Invest. 2014 Jun 2;124(6):2325–32.
512	
52153 514 515	Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T, Chakravarthy U. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet. 2006 Oct;38(10):1173–7.
516	
52167. 518	Thurman JM, Harrison RA. The susceptibility of the kidney to alternative pathway activation-A hypothesis. Immunol Rev. 2023 Jan 1;313(1):327–38.
519	
52270 521 522	Sun Z, Zhang Z, Banu K, Gibson IW, Colvin RB, Yi Z, et al. Multiscale genetic architecture of donor- recipient differences reveals intronic LIMS1 mismatches associated with kidney transplant survival. J Clin Invest. 2023 Sep 7;
523	
52284 525 526	Rasmi Y, Jalali L, Khalid S, Shokati A, Tyagi P, Ozturk A, et al. The effects of prolactin on the immune system, its relationship with the severity of COVID-19, and its potential immunomodulatory therapeutic effect. Cytokine. 2023 Sep 1;169:156253.

Markkinen et al

Sellin L, Huber TB, Gerke P, Quack I, Pavenstädt H, Walz G. NEPH1 defines a novel family of podocin
 interacting proteins. The FASEB journal^[2]: official publication of the Federation of American Societies
 for Experimental Biology. 2003;17(1):115–7.

531

Lamarthée B, Genet C, Cattin F, Danger R, Giral M, Brouard S, et al. Single-cell mapping of leukocyte
immunoglobulin-like receptors in kidney transplant rejection. Frontiers in Transplantation. 2022 Aug
11;1:952785.

535

Mitchell A, Rentero C, Endoh Y, Hsu K, Gaus K, Geczy C, et al. LILRA5 is expressed by synovial tissue
 macrophages in rheumatoid arthritis, selectively induces pro-inflammatory cytokines and IL-10 and
 is regulated by TNF-alpha, IL-10 and IFN-gamma. Eur J Immunol [Internet]. 2008 [cited 2024 Jun

539 19];38(12):3459–73. Available from: https://pubmed.ncbi.nlm.nih.gov/19009525/

540

- 53421. Truong AD, Hong Y, Nguyen HT, Nguyen CT, Chu NT, Tran HTT, et al. Molecular identification and
- 542 characterisation of a novel chicken leukocyte immunoglobulin-like receptor A5. Br Poult Sci
- 543 [Internet]. 2021 [cited 2024 Jun 19];62(1):68–80. Available from:
- 544 https://pubmed.ncbi.nlm.nih.gov/32812773/

545

Markkinen et al

547 Table 1. Characteristics of the study cohort.

			Patients with			
	All patients,	Patients with	rs 7542235			
Characteristic	n = 1025	rs7542235 GG	AA/AG	P-value [®]		
		genotype, n = 15	genotype, n =			
			1010			
Age (median, range)	57 (18 2 79)	58 (36274)	57 (18279)	0.639°		
Sex, n (%)				1 ^d		
Male	703 (69)	10 (67)	693 (69)			
Female	322 (31)	5 (33)	317 (31)			
Rejection, n (%)	199 (19)	8 (53)	191 (19)	<0.001 ^d		
T cell -mediated, n (%)	178 (17)	6 (75)	172 (90)			
Antibody-mediated, n (%)	21(3)	2 (25)	19 (10)			
Primary diagnosis, n (%)						
Polycystic kidney disease	202 (20)	3 (20)	199 (20)	1 ^e		
Diabetic nephropathy with type diabetes	150 (15)	2 (13)	148 (15)	1 ^e		
lgA nephropathy	106 (10)	2 (13)	104 (10)	0.662 ^e		
Chronic kidney disease, unspecified	105 (10)	2 (13)	103 (10)	0.660 ^e		
Glomerular disorder in amyloidosis	6 (1)	1(7)	5 (1)	0.085 [°]		
Glomerular disorder in polyarteritis nodosa	4 (0)	1(7)	3 (0)	0.057 ^e		
Glomerular disorder in granulomatosis with	10 (1)	1 (7)	0 (1)	0 127 ^e		
polyangiiti s	10 (1)	1 (7)	9 (1)	0. 137 ^e		
Hydronephrosis with ureteropelvic junction	2 (0)	4 (7)	4 (0)	0.000		
obstruction	2 (0)	1 (7)	1 (0)	0.029 [°]		
Other chronic kidney disease	22 (2)	1(7)	21 (2)	0. 279 ^e		
Polycystic kidney disease, unspecified	9 (1)	1(7)	8 (1)	0. 124 ^e		
Oth er	409 (40)	O (O)	409 (40)	<0.001 ^e		
	М	edian (IQR)				
Death-censored follow-up time, months	37 (18263)	37 (9250)	37 (18263)	0.402 ^c		
PRA >0, % ^b	22 (5255)	52 (20264)	21 (5255)	0.290 ^c		
PRA >0, % ^b	27 (12260)	17 (17258)	27 (12260)	0.702 ^c		
Cold ischemia, hours	20 (17223)	21 (19222)	20 (17223)	0.569 ^e		
HLA eplet mismatch sum, n	27 (19236)	28 (17246)	27 (19236)	0.808 ^c		
HLA eplet mismatch sum, n	11 (7215)	9 (71213)	11 (7215)	0.459 [°]		
HLA II eplet mismatch sum, n	16 (7⊡24)	22 (8228)	16 (7224)	0.388°		

548

HLA, human leukocyte antigen; IgA, Immunoglobulin A; IQR, interquartile range; PRA, panel-reactive antibody.

549 ^aThe significance of variation was calculated between rs7542235 GG vs. AG/AA groups.

550 ^bThe medians of PRA values are calculated only from patients with PRAI >0 and PRAII >0.

551 ^cThe Mann–Whitney U-test.

^dThe Pearson chi-square test. 552

553 ^eFisher's exact test.

554 ^fThe Student's t-test.

Markkinen et al

555 Table 2. Characteristics of the 15 patients with rs7542235 GG-genotype tagging for homozygous CFHR321

556 deletion. Rejection vs. non-rejection group.

Characteristic	Patients with rs7542235 GG genotype, n = 15	Patients with rs7542235 GG genotype with rejection, n = 8	Patients with rs7542235 GG genotype without rejection, n = 7	P-value [®]
Age (median, range)	58 (36-74)	52 (36-73)	61 (53-74)	0.064 ^c
Sex, n (%)				0.854 ^d
Male	10 (67)	6 (75)	4 (57)	
Female	5 (33)	2 (25)	3 (43)	
Rejection, n (%)	8 (50)	8 (100)	O (O)	
T cell -mediated, n (%)	6 (38)	6 (75)	O (O)	
Antibody-mediated, n (%)	2 (12)	2 (25)	0 (0)	
Primary diagnosis, n (%)				
Polycystic kidney disease	3 (20)	O (O)	3 (43)	0.076 ^e
Diabetic nephropathy with type I diabetes	2 (13)	1 (12.5)	1 (14)	1 ^e
lgA nephropathy	2 (13)	2 (25)	O (O)	0.466 ^e
Chronic kidney disease, unspecified	2 (13)	2 (25)	O (O)	0.466 ^e
Glomerular disorder in amyloidosis	1(7)	1 (12.5)	0 (0)	1 ^e
Glomerular disorder in polyarteritis nodosa	1 (7)	0 (0)	1 (14)	0.466 ^e
Glomerular disorder in granulomatosis with polyangiitis	1 (7)	1 (12.5)	0 (0)	1 ^e
Hydronephrosis with ureteropelvic junction obstruction	1 (7)	0 (0)	1 (0)	0.466 ^e
Other chronic kidney disease	1(7)	O (O)	1 (14)	0.466 ^e
Polycystic kidney disease, unspecified	1(7)	1 (12.5)	0 (0)	1 ^e
	Med	lian (IQR)		
Follow-up time, months	37 (9-50)	29 (9-40)	41 (24-70)	0.189 ^c
PRA >0, % ^b	52 (20-64)	52 (36-62)	36 (22-50)	NA^{f}
PRA >0, % ^b	17 (17-58)	17 (17-17) ^g	99 (99-99) ^h	NA^{f}
Cold ischemia, hours	21 (19-22)	22 (19-23)	21 (19-22)	0.491 ^f
HLA eplet mismatch sum, n	28 (17-46)	38 (23-49)	27 (14-33)	0.182 ^c
HLA eplet mismatch sum, n	9 (7-13)	12 (7-19)	9 (8-11)	0.521 ^c
HLA eplet mismatch sum, n	22 (8-28)	23 (14-30)	8 (7-25)	0.269 ^c

557 HLA, human leukocyte antigen; IgA, Immunoglobulin A; IQR, interquartile range; PRA, panel-reactive antibody.

559 rs7542235 GG-genotype.

^bThe medians of PRA values are calculated only from patients with PRAI >0 and PRAII >0.

561 ^cThe Mann–Whitney U-test.

^dThe Pearson chi-square test.

563 ^eFisher's exact test.

^{558 &}lt;sup>a</sup>The significance of variation was calculated between rejection and non-rejection group of patients with

Markkinen et al

- ^fThe significance of variation was not analyzed due to the low frequency count.
- 565 ^gn = 2
- 566 ^hn = 1
- 567 ^fThe Student's t-test.

Markkinen et al

569 Table 3. Detailed description of serum samples.

Sample ID (pseudonymized)	Sample number in the Figure 5	Pre-tx sample	Post-tx sample	The region for homozygous deletion according to MLPA/WGS	The region for heterozygous deletion according to MLPA/WGS	Rejection*
ABGR4XFUNH	1	x		CFHR3 (exons 1₪6), CFHR1 (exons 1₪6)		0
ABGR4XFUNH	2		x	CFHR3 (exons 126), CFHR1 (exons 126)		0
BCZORKR4A3	3	x		CFHR3 (exons 1₪6), CFHR1 (exons 1₪6)		0
DGYMLR5QCF	4	x		no deletion control sample		0
EN257NXZIH	5	x		CFHR3 (exons 1⊠6), CFHR1 (exons 1⊠6)		0
NQZTUVJ6JA	6	x		CFHR3 (exons 1₪6), CFHR1 (exons 1₪6)		0
3RVWTIW47P	7	x		CFHR3 (exons 126), CFHR1 (exons 126)		1
3RVWTIW47P	8		x	CFHR3 (exons 126), CFHR1 (exons 126)		1
ADCKGCMCUK	9	x		CFHR3 (exons 126), CFHR1 (exons 126)		1
ADCKGCMCUK	10		x	CFHR3 (exons 126), CFHR1 (exons 126)		1
JUIHLJXRHX	11	x		CFHR1 (exons 1⊡6)	CFHR3 (exons 1₪6), CFHR4 (exons 1₪10)	1
JUIHLJXRHX	12		x	CFHR1 (exons 126)	CFHR3 (exons 1₪6), CFHR4 (exons 1₪10)	1
QDM 2EBUWCF	13	x		CFHR3 (exons 1⊠6), CFHR1 (exons 1⊠6)		1
QDM 2EBUW CF	14		x	CFHR3 (exons 1⊠6), CFHR1 (exons 1⊠6)		1
V53C3LDXJW	15	x		CFHR3 (exon 6), CFHR1 (exons 1⊡6)	CFHR3 (exons 1₪4), CFHR4 (exons 1₪6)	1
V53C3LDXJW	16		x	CFHR3 (exon 6), CFHR1 (exons 1⊡6)	CFHR3 (exons 1₪4), CFHR4 (exons 1₪6)	1

570 CFHR, complement factor H related; MLPA, multiplex ligation-dependent probe amplification; WGS, whole genome

571 sequencing; *Acute rejection status 0 = no rejection, 1 = rejection

Markkinen et al

573 Table 4. eQTL associations of CFHR3[®]1 deletion tagging variants rs7542235 and rs6677604.

			FIVEx			
Gene	Tissue	Chromosome	Assessed allele	Other allele	Effect size	P-value
CFHR1	blood vessel	1	G	A	-0.48	7.59 x 10 ⁰⁶
CFHR1	kidn ey	1	G	А	- 1. 68	0.00
CFHR1	blood vessel	1	G	А	-0.43	0.02
CFHR1	blood vessel	1	G	А	-0.08	0.35
CFHR3	blood vessel	1	G	А	-0.92	1.17 x 10 ⁻²³
CFHR3	blood vessel	1	G	A	- 0. 78	191×10 ¹⁶
CFHR3	blood vessel	1	G	A	- 0. 96	4.17 x 10 ⁻¹¹
CFHR3	kidn ey	1	G	A	- 1.64	0.00
CFHR4	kidn ey	1	G	А	- 0. 98	0.02
			eQTLGen Conso	ortium		
Gene	Tissue	Chromosome	Assessed allele	Other allele	Z-score	P-value
CFH	Blood	1	G	А	10.05	8.88 x 10 ⁻²⁴
			Human Kidney eC)TL Atlas		
Gene	Tissue	Chromosome	Assessed allele	Other allele	Beta *	P-value
CFHR1	kidney tubule	1	G	A	-0.77	2.73 x 10 ⁵⁸
CFHR3	kidney tubule	1	G	А	-0.33	4.01 x 10 ⁻¹⁰
		∆CFHI	₹3⊡1-tagging vari	ant rs6677604		
			FIVEx			
Gene	Tissue	Chromosome	Assessed allele	Other allele	Effect size	P-value
CFH	kidn ey	1	А	G	0.05	0.84
CFH	blood vessel	1	А	G	0.09	0.32
CFHR1	blood vessel	1	А	G	-0.49	1.55 x 10 ⁻⁵
CFHR1	kidn ey	1	А	G	- 1. 68	1.11 × 10 ⁻³

Markkinen et al

Gene	Tissue	Chromosome	Assessed allele	Other allele	Z-score	P-value
			eQTLGen Conso	ortium		
KCNT2	kidn ey	1	А	G	-0.079	0.78
KCNT2	blood vessel	1	А	G	-0.06	0.63
KCNT2	blood vessel	1	А	G	-0.07	0.43
CFHR4	kidn ey	1	А	G	-0.98	0.02
CFHR3	kidn ey	1	А	G	- 1. 64	1.51 x 10 ⁻³
CFHR3	blood vessel	1	А	G	- 1.01	1.07 x 10 ⁻¹⁰
CFHR3	blood vessel	1	А	G	-0.81	1.91 x 10 ⁻¹⁶
CFHR3	blood vessel	1	А	G	-0.94	5.37 x 10 ⁻²³
CFHR1	blood vessel	1	А	G	-0.08	0.40
CFHR1	blood vessel	1	А	G	-0.40	0.04

CFH	Blood	1	A	G	9.96	2.18 x 10 ⁻²³	
Human Kidney eQTL Atlas							
Gene	Tissue	Chromosome	Assessed allele	Other allele	Beta *	P-value	

CFHR1	kidney tubule	1	А	G	-0.73	8.42 x 10 ^{.51}
CFHR3	kidney tubule	1	А	G	-0.33	4.69 x 10 ⁻¹⁰

574 *Effect size (Beta) is reported with respect to the alternate allele. CFH, complement factor H; CFHR, complement factor H

575 related; eQTL, expression quantitative trait loci; KCNT2, potassium channel subfamily T, member 2.

576

Markkinen et al

578 Table 5. pQTL associations of CFHR321 deletion tagging variants rs7542235 and rs6677604 in Olink and

579 SomaScan data.

△CFHR1-tagging variant rs7542235

		Olink (n = 12	25)		
Gene	Chromosome	Assesse d allele	Other allele	Beta	P-value
CFH	1	G	А	0.42	2.34 x 10 ⁻¹²
CFH R2	1	G	А	0.38	2.54 x 10 ⁻¹⁰
CFH R5	1	G	А	0.33	2.97 x 10 ⁻⁰⁸
		SomaScan (n =	= 865)		
Gene	Chromosome	Assesse d allele	Other allele	Beta	P-value
AKR 1B 10	7	G	А	-0.87	6.01 x 10 ⁻³⁷
CFH	1	G	А	0.37	1.81 x 10 ⁻⁰⁷
CFH R1	1	G	А	-0.82	1.05 x 10 ⁻³³
CFH R5	1	G	А	0.40	9.31 x 10 ⁻⁰⁹
DYNLT3	Х	G	А	0.37	1.95 x 10 ^{.07}
F13B	1	G	А	0.43	5.31 x 10 ⁻¹⁰
GLT8D1	3	G	А	-0.41	5.62 x 10 ^{.09}
KIRREL1	1	G	А	0.35	4.78 x 10 ^{.07}
LRP1B	2	G	А	-0.34	9.86 x 10 ^{.07}
MAN 1B1	9	G	А	0.45	1.97 x 10 ⁻¹⁰
MYCT1	6	G	А	-0.33	3 34 x 10 ⁰⁶
NAGLU	17	G	А	-0.63	1.11 x 10 ⁻¹⁹
NDUFS4	5	G	А	0.64	1.08 x 10 ⁻²⁰
OTOR	20	G	А	-0.41	6.56 x 10 ^{.09}
PRLR	5	G	А	- 1.03	9.62 x 10 ⁻⁵⁵
RIPPLY3	21	G	А	0.61	1 14 x 10 ⁻¹⁸
RPS6KA1	1	G	А	-0.42	2.68 x 10 ^{.09}
SCRN3	2	G	А	0.55	1.63 x 10 ⁻¹⁵
TST	22	G	А	0.48	6.90 x 10 ⁻¹²
UGT2B15	4	G	А	0.56	1.25 x 10 ⁻¹⁵
ULBP2	6	G	А	0.44	3.29 x 10 ⁻¹⁰
ZDHHC4	7	G	А	0.33	3.50 x 10 ^{.06}

△CFHR3 21-tagging variant rs6677604

		Olink (n = 1225)		
Gene	Chromosome	Assesse d	Other allele	Beta	P-value

Markkinen et al

		allele			
CFH	1	G	A	0.41	5.40 x 10 ⁻¹⁷
LILRA5	19	G	А	0.27	2.87 x 10 ⁻⁸
		SomaScan (n =	= 865)		
Gene	Chromosome	Assesse d allele	Other allele	Beta	P-value
CFH R1	1	G	А	-0.86	4.57 x 10 ⁻³⁶
NAGLU	17	G	А	-0.64	5.89 x 10 ⁻²⁰
OTOR	20	G	А	-0.43	1 78 x 10 ⁹
PRLR	5	G	А	- 1.03	3.04 x 10 ⁻⁵³
RIPPLY3	21	G	А	0.63	3.48 x 10 ^{.19}

Markkinen et al

581 FIGURE LEGENDS

582 Figure 1. MLPA results for rs7542235 GG genotype patients with rejection (A) and without

- 583 rejection (B). Deletion type 1 indicates homozygous deletion at CFHR3 exons (ex) 126 and
- 584 CFHR1 ex 126. Deletion type 2 indicates homozygous deletion at CFHR1 ex 226 and
- heterozygous deletions at CFHR3 ex 126 and CFHR4 ex 1210. Deletion type 3 indicates
- 586 homozygous deletion at CFHR3 ex 6 and CFHR1 ex 126 and heterozygous deletions at CFHR3
- 587 ex 124 and CFHR4 ex 126. CFHR, complement factor H related; MLPA, multiplex ligation-
- 588 dependent probe amplification.

589 Figure 2. MLPA results for rs7542235 AA genotype (A) and AG genotype (B) patients.

- 590 Patients with rs7542235 AA genotype had normal genotype without deletions. Patients with
- rs7542235 AG genotype carried a heterozygous deletion covering *CFHR3* ex 1[®]6 and *CFHR1*
- ex 126. CFHR, complement factor H related; MLPA, multiplex ligation-dependent probe
- 593 amplification.

594 Figure 3. The results of whole genome sequencing of CFHR321 loci on chromosome 1 for

10 rs7542235 GG genotype patients. The turquoise color represents a homozygous

596 deletion, and the dark blue heterozygous deletion. The three lowest samples were

- sequenced at the time of Study I, other samples were sequenced at the time of Study II. The
- 598 IDs on the left indicate the pseudonymes for each patient. The variant rs7542235 tagging for
- the deletion $\Delta CFHR1$ is located in the intergenic region between CFHR1 and CFHR4, and the
- 600 variant rs6677604 tagging for deletion Δ*CFHR3* [□]*I* is located in the intron 11 of *CFH* gene
- 601 (red bars). Each patient with homozygous deletion $\Delta CFHR3$ 21 were homozygous for
- rs6677604 AA genotype, while rest of the patients were heterozygous AG for that variant.
- 603 CFH, complement factor H; CFHR, complement factor H related; ID, identity.

604 Figure 4. Detailed illustration of MLPA and WGS results for Deletion type 3. Patient with


homozygous deletion covering CFHR3 exon 6 and CFHR1 exons 126, and heterozygous


- 606 deletions covering CFHR3 exons 124 and CFHR4 exons 124. A) CFH/CFHR gene locus, exons
- and deletions of patient V53C3LDXJW. B) MLPA result for the CFH/CFHR locus. The deletion
- is denoted by the red spots below the deletion cut-off line (red) in the ratio chart. The red
- line represents the 0.7 ratios, and the blue line represents the 1.3 ratios. Above the blue line

Markkinen et al


610	are the genes co	vered by the SALS	A MLPA probemix, P2	236 CFH Region B1.	C) Visualization
-----	------------------	-------------------	---------------------	--------------------	------------------


- of homozygous deletion in WGS data at the beginning of *CFHR3* gene exon 6. Control
- sample without deletion above, the patient sample below. D) Visualization of heterozygous
- 613 deletion in WGS data at the end of *CFHR4* gene. The coverage (gray) decreases half in size at
- 614 the heterozygous deletion region. CFH, complement factor H; CFHR, complement factor H
- related; MLPA, multiplex ligation-dependent probe amplification; WGS, whole genome
- 616 sequencing.
- **Figure 5. Western blot analyses of FH and FHR-1 protein expression.** The detailed
- 618 information for each serum sample is described in Table 3. The sample number 4 (control)
- and normal human serum (NHS, also control) have normal expression of FHR1. The other
- samples are individuals with homozygous deletion of *CFHR1* gene. FH, factor H protein; FHL-
- 1, factor H like protein 1; FHR-1, factor H related protein 1; kDa, kilodalton; MK, marker;
- 622 NHS, normal human serum
- 623
- 624







Homozygous Heterozygo deletion deletion









Chr 1

